CONTEXT: The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC. EVIDENCE ACQUISITION: For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering the Medline, EMBASE, and Cochrane databases. The data search focused on randomised controlled trials (RCTs) and retrospective or controlled comparator-arm studies, SRs, and meta-analyses. Evidence synthesis was conducted using modified GRADE criteria as outlined for all the EAU guidelines. EVIDENCE SYNTHESIS: All chapters of the RCC guideline were updated on the basis of a structured literature assessment, and clinical practice recommendations were developed. The majority of the studies included were retrospective with matched or unmatched cohorts and were based on single- or multi-institution data or national registries. The exception was systemic treatment of metastatic RCC, for which there are several large RCTs, resulting in recommendations that are based on higher levels of evidence. CONCLUSIONS: The 2022 RCC guidelines have been updated by a multidisciplinary panel of experts using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2022. PATIENT SUMMARY: The European Association of Urology panel for guidelines on kidney cancer has thoroughly evaluated the research data available to establish up-to-date international standards for the care of patients with kidney cancer.

Academic Urology Unit University of Aberdeen Aberdeen UK; Department of Urology Aberdeen Royal Infirmary Aberdeen UK

Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France

Department of Surgical and Perioperative Sciences Urology and Andrology Umeå University Umeå Sweden

Department of Translational Medicine Division of Urological Cancers Lund University Malmö Sweden

Department of Urology Cabueñes University Hospital Gijón Spain

Department of Urology Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel

Department of Urology Charité Universitätsmedizin Berlin Berlin Germany

Department of Urology Coimbra University Hospital Coimbra Portugal

Department of Urology Darent Valley Hospital Dartford and Gravesham NHS Trust Dartford UK

Department of Urology San Raffaele Scientific Institute Milan Italy; Division of Experimental Oncology Unit of Urology URI IRCCS San Raffaele Hospital Milan Italy

Department of Urology Sunderby Sjukhus Umeå University Luleå Sweden

Department of Urology University Hospital Pilsen and Faculty of Medicine in Pilsen Charles University Prague Czech Republic

Department of Urology University Hospital Tuebingen Tuebingen Germany; German Cancer Consortium and German Cancer Research Center Heidelberg Germany

Department of Urology University of Eastern Piedmont Maggiore della Carità Hospital Novara Italy

International Kidney Cancer Coalition Duivendrecht The Netherlands

The Royal Free London NHS Foundation Trust London UK; UCL Division of Surgery and Interventional Science London UK; Department of Urology The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam The Netherlands

The Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK

Komentář v

Eur Urol. 2022 Sep;82(3):e88. doi: 10.1016/j.eururo.2022.05.038. PubMed

Citace poskytuje Crossref.org

A retrospective single-center pilot study of the genetic background of the transplanted kidney

Computed tomography-guided percutaneous biopsy in diagnosis of suspected metastatic renal cell carcinoma: which location is the most suitable?

Stereotactic Body Radiotherapy (SBRT) for the Treatment of Primary Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis

Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review

Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review